The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|January 28, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-02-03-2016
- Volume 12
- Issue 2
Vetter Completes Development and IT Facility
Author(s)Pharmaceutical Technology Editors
Vetter announces completion of multi-functional building for development service and IT functions.
Advertisement
Vetter announced on Jan. 28, 2016 that the company’s Schuetzenstrasse multi-functional building in Ravensburg, Germany, has been completed on schedule and departments critical to its operation have started to move in. The €29 million investment is part of a €300 million total investment strategy announced by the company in September 2015 for further development to its manufacturing sites.
The continued demand by large and small customers for enhanced drug development services, as well as the need for ever-more future-oriented sophisticated IT systems to protect their data, created the need for the new facility, the company reported in a press statement.
The 91,500-sq ft, six-story building contains non-cGMP laboratories for development support, laboratory space for microbiological analysis, office workplaces for Vetter Development Service and IT, and a data processing center with enhanced security systems, including a safety cell that protects technology and data from external physical hazards in the event of an emergency.
Source:
Articles in this issue
over 10 years ago
Is Consolidation Good for Pharma?over 10 years ago
Parenteral Packagers Focus on Security and Supply-Chain Transparencyover 10 years ago
Hermes Pharma Adds Hot Melt Coating Capabilityover 10 years ago
Novasep Adds Small-Scale Manufacturing Capability to US Facilityover 10 years ago
Adents, Siemens Team on Serialization Solutionover 10 years ago
Onyx Scientific Announces Facility Expansionover 10 years ago
FDA’s CDER Previews 2016 Guidance AgendaAdvertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Advertisement
Advertisement